Cancer
Hedgehog pathway inhibitors (vismodegib)
Drugs that block Smoothened, the switch of the Hedgehog pathway, which is abnormally active in nearly all basal cell carcinomas; used when the tumour is locally advanced or metastatic and cannot be treated by surgery or radiotherapy.
Mechanism of action
- Normally PTCH1 restrains Smoothened (SMO); Hedgehog ligand releases it, activating GLI transcription factors.
- In basal cell carcinoma, loss of PTCH1 (or activating SMO mutations) switches the pathway on permanently.
- Vismodegib and sonidegib bind and inhibit SMO, switching off GLI-driven growth.
Molecular targets
- Smoothened (SMO): Antagonist
Drugs in Hedgehog pathway inhibitors (vismodegib)
- Vismodegib (By mouth.)
- Sonidegib
Therapeutic uses
- Locally advanced basal cell carcinoma not suitable for surgery or radiotherapy
- Metastatic basal cell carcinoma
Diseases it treats
Adverse effects
- Muscle spasms
- Hair loss
- Loss of taste and weight loss
- Fatigue
Contraindications by condition
- Pregnancy (Contraindicated): Hedgehog signalling patterns the embryo: severe birth defects or fetal death. Strict contraception for both sexes, and no blood donation.
- Breastfeeding (Contraindicated): It may harm the infant.
Written from
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 54, Cancer Chemotherapy, Hedgehog pathway inhibitors
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 61, Dermatologic Pharmacology, Basal cell carcinoma: hedgehog inhibitors
Educational reference. Not medical advice, diagnosis or treatment.